Abstract
AbstractB cells and antibodies are increasingly recognized as an important feature in a broad variety of autoimmune and infectious central nervous system (CNS) diseases, such as multiple sclerosis, neuromyelitis optica, paraneoplastic diseases, acute demyelinating encephalomyelitis, Sydenham chorea, stiff‐person syndrome and channelopathies. Autoantibodies might serve as a biomarker to identify the disease entity. Beyond this, autoantibodies can be a relevant pathogenic component. The present review focuses on strategies applied to identify the targets of autoantibodies and to test their pathogenetic relevance. The pathways of autoantibodies into and out of the CNS are summarized and the issue whether pathogenicity requires recognition of an extracellular target is discussed. (Clin. Exp. Neuroimmunol. doi: 10.1111/j.1759‐1961.2009.00006.x, 2010)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
